Venture Capital

CRB Inverbio is a private venture capital management firm specialized in life sciences investing in innovative early stage start- ups in biotech, med tech, digital health and medical technologies

Advisory Firm

Leveraging its extended network and experience, CRB Inverbio provides advise and partner with emerging technology companies in their field of expertise to help them develop their development strategy and financing options.

Early Stage Investments

CRB Inverbio continue to explore new investments opportunities and nurtures a live deal flow and investments opportunities with high potential.

100%

Breakthrough Healthcare Investments

  • Led by a senior and experienced team with sound track record in identifying science and technology of excellence and translating it into market opportunities and a large network and access to high potential deal flow.
  • Investment model includes hands on approach and access to a broad network of expertise: SAB, venture partners, portfolio CEOs, KOLs and best in class local and global partners.
  • CRB Inverbio has forged agreements with the top scientific biomedical research organisations and Life Science accelerators in Spain.
  • With more than €50M under management, CRB Inverbio portfolio includes some of the most promising healthcare technology based companies in Spain.
  • CRB Funds fill a gap in the market and contribute to accelerate industry and sector development.
  • CRB Inverbio SGEIC, SA is registered at the Spanish Securities and Exchange Commission (CNMV).

Investment Approach

 

  • Originated in a Research Institution with links to the National Health System
  • Disruptive solution to an unmet global clinical need
  • Global scope, big markets and existence of potential customers and partners
  • Solid IP Protection and “freedom to operate”
  • POC/Clinical evidence · Clear Regulatory pathway
  • Experienced promotors and management team
  • Clear space for divestment opportunities – high return opportunities

 

LOADING

Venture Capital

Advisory Firm

Early Stage Investments